Oramed Pharmaceuticals (ORMP) closed at $4.07 on October 16, 2026, down 2.6% from the previous close, on volume of 276,093 shares (30-day average 164,883).
Data as of October 16, 2026.
16-Oct-2026
No headlines found.
Globe Newswire (Mon, 17-Aug 8:00 AM ET)
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Oramed Pharmaceuticals trades on the NASDAQ stock market under the symbol ORMP.
As of October 16, 2026, ORMP stock price declined to $4.07 with 276,093 million shares trading.
ORMP has a beta of 0.76, meaning it tends to be less sensitive to market movements. ORMP has a correlation of 0.03 to the broad based SPY ETF.
ORMP has a market cap of $169.30 million. This is considered a Micro Cap stock.
In the last 3 years, ORMP traded as high as $5.47 and as low as $1.67.
The top ETF exchange traded funds that ORMP belongs to (by Net Assets): IWM, IWN, VTWO, IWC, DFAS.
ORMP has outperformed the market in the last year with a return of +90.3%, while the SPY ETF gained +16.7%. However, in the most recent history, ORMP shares have underperformed the stock market with its stock returning +0.5% in the last 3 month period and -9.4% for the last 2 week period, while SPY has returned +1.9% and -0.8%, respectively.
ORMP support price is $4.07 and resistance is $4.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ORMP shares will trade within this expected range on the day.
